Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

Manhattan Behavioral Medicine, New York

Alzheimer's Memory Center and Research Institute, Charlotte

Progressive Medical Research, Port Orange

Anchor Neuroscience, Pensacola

Florida Premier Research Institute, Winter Park

Miami Dade Medical Research Institute, Miami

Suncoast Neuroscience Associates, Inc., St. Petersburg

Sensible Healthcare, LLC, Ocoee

Northwest Clinical Trials, Boise

Alliance for Research, Long Beach

Pacific Research Network, San Diego

Viking Clinical Research, Temecula

CITrials, Santa Ana

Southern California Research, LLC, Simi Valley

Northwest Clinical Research Center, Seattle

MassGeneral Institute for Neurodegenerative Disease, Charlestown

Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s., Choceň

Cerebrovaskulární poradna s.r.o., Moravská Ostrava

Clintrial S.R.O, Prague

Private Psychiatric Centre, Prague

Vestra Clinics S.R.O, Rychnov nad Kněžnou

CCBR Clinical Research, Aalborg, Aalborg

CCBR Clinical Research, Ballerup, Ballerup Municipality

CCBR Clinical Research, Vejle, Vejle

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

Alzheimer Research Center, Amsterdam

Amphia Ziekhuis, Breda

MAC Clinical Research Tankersley, Barnsley

Re:Cognition Health Birmingham, Birmingham

MAC Clinical Research Blackpool, Blackpool

Fulbourn Hospital, Cambridge

MAC Clinical Research Leeds, Leeds

MAC Clinical Research Liverpool, Liverpool

Re:Cognition Health London, London

St. Pancras Clinical Research, London

MAC Clinical Research Manchester, Manchester

Re:Cognition Health Plymouth, Plymouth

5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust, Warrington